DarioHealth Corp
DRIO
View Detailed Chart
6.600USD
+0.430+6.97%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
15.01MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+6.97%
5 Days
-7.17%
1 Month
+1400.00%
6 Months
+816.67%
Year to Date
+739.59%
1 Year
+560.07%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
25.500
Target Price
+313.29%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
DarioHealth Corp. is a global digital therapeutics (DTx) company. The Company operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutic interventions. Its platform and suite of solutions delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its products include Dario Blood Pressure Monitoring System and Dario Blood Glucose Monitoring Starter Kit. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all its user readings in the Dario App. Its Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
Growing
The company is in a growing phase, with the latest annual income totaling USD 27.04M.
Undervalued
The company’s latest PE is -8.38, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 17.15M shares, decreasing 10.78% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 18.18K shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
DarioHealth Corp. is a global digital therapeutics (DTx) company. The Company operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutic interventions. Its platform and suite of solutions delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its products include Dario Blood Pressure Monitoring System and Dario Blood Glucose Monitoring Starter Kit. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all its user readings in the Dario App. Its Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
Ticker SymbolDRIO
CompanyDarioHealth Corp
CEOMr. Erez Raphael
Websitehttps://shop.mydario.com/
Related Instruments
+1.09%
-0.27%
-0.53%
-0.28%
-0.71%
+0.10%
-0.69%
-10.99%
-0.69%
-0.80%
-0.12%
-0.05%
-0.49%
+1.41%
-0.87%
-2.83%
-0.83%
-0.89%
-1.01%
+0.33%
